Long-term Treatment Outcome for Stage III NPC Patients and Risk Grouping by Plasma EBV DNA

Long-term Treatment Outcome for Stage III Nasopharyngeal Carcinoma Patients and Risk Grouping by Plasma Epstein-Barr Virus DNA

No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The investigators try to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma Epstein-Barr virus (EBV) DNA assay for future therapy improvement.

The stage III NPC patients were the majority group of the patient population of NPC. But most clinical trials focused on the treatment of American Joint Committee on Cancer (AJCC) 7th edition stage IVA/IVB treatment for high risk of recurrence or metastasis. No previous study reported the treatment outcome of stage III NPC patients. The investigators tried to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma EBV DNA assay for future therapy improvement.

Inclusion Criteria:

• Biopsy-proven stage III nasopharyngeal carcinoma (NPC)
• Finished curative chemoradiotherapy
• Have Pre-treatment and post-radiotherapy plasma EBV DNA

Exclusion Criteria:

• No tissue proven NPC
• Not finished curative treatment
• No Pre-treatment and post- radiotherapy plasma EBV DNA